Ikena Oncology (IKNA) Q4 2025 earnings summary

Executive summary

• Ongoing Phase 2b ADAPTIVE trial for IMG-007 in moderate-to-severe atopic dermatitis, with topline data expected in 2027; favorable safety profile observed to date.

• Protocol amendment submitted to expand dosing regimens and optimize study design.

• Key leadership additions in 2025 and early 2026, including new CEO and CMO.

• Company formed via reverse merger with Ikena Oncology and $75M private placement in July 2025.

Financial highlights

• Ended 2025 with $135.3M in cash, cash equivalents, and marketable securities, up from $12.1M at end of 2024, mainly due to merger and private placement.

• R&D expenses for Q4 2025 were $3.3M, down from $3.8M in Q4 2024.

• G&A expenses for Q4 2025 were $5.2M, up from $2.4M in Q4 2024, driven by merger-related costs and increased personnel expenses.

• Net loss for Q4 2025 was $6.9M, compared to $4.8M in Q4 2024; full-year 2025 net loss was $45.3M, up from $36.6M in 2024.

• Weighted average shares outstanding (common stock) increased to 4.87M in 2025 from 1.19M in 2024.

Outlook and guidance

• ADAPTIVE trial enrollment on track, with topline data expected in 2027.

• Continued focus on expanding safety database and differentiating IMG-007’s efficacy and safety profile.

• Ongoing evaluation of Kaposi’s sarcoma risk and OX40-OX40L signaling in AD population.